Cellectar Biosciences, Inc. (CVM, Financial) has announced the pricing of its latest stock offering at a value below its previous closing price of $4.51. This strategic move is managed by ThinkEquity, which is serving as the exclusive book-running manager for this offering.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for CEL-SCI Corp (CVM, Financial) is $222.00 with a high estimate of $300.00 and a low estimate of $180.00. The average target implies an upside of 4,822.39% from the current price of $4.51. More detailed estimate data can be found on the CEL-SCI Corp (CVM) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, CEL-SCI Corp's (CVM, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
